The Health Natural Language Processing Lab at Boston Children’s Hospital is seeking a post-doctoral research fellow to contribute to cutting edge research in the field of health natural language processing. This project will develop deep neural network methods for representing and summarizing the text in electronic health records, with high impact clinical applications.

The diversity of subject matter will require a creative candidate with the passion and diligence to solve challenging problems in an interdisciplinary environment. The Research Fellow will be expected to lead publications, and will receive enthusiastic mentorship with the goal of preparing and submitting a career development award proposal, as well as other research proposals as appropriate.

This position provides an excellent opportunity for the Research Fellow to work within a multidisciplinary research team to explore advanced areas in health information technology. CHIP is home to 20 faculty working at the forefront of research areas extending beyond clinical NLP to digital epidemiology, clinical genomics, and app ecosystems for health records. CHIP and the Health NLP Lab value diversity and believe that it is essential to achieving excellence. We therefore strongly encourage candidates from underrepresented groups to apply. The fellowship includes an academic appointment at Harvard Medical School, as well as a hospital appointment at Boston Children’s Hospital.

Admissions

The position is available immediately and is renewable annually.

Qualifications
  • PhD degree in computer science, information science, computational linguistics, biomedical informatics, data mining,
    or a closely related field.
  • Experience in research; ability to plan and carry out research experiments and projects.
  • Candidates with experience in the areas of machine learning, natural language processing/computational linguistics, and medical terminologies/ontologies are strongly encouraged to apply.
  • Programming experience in computer programming languages (e.g., Python, Java, etc).
  • Strong written and oral communication skills required.
  • Ability to work both independently and as a team player. 
How to apply

Interested candidates should email a CV, three letters of reference, and a sample publication to
Prof. Timothy Miller, PI Natural Language Processing Lab tim.miller@gmail.com

Publications

Hopper RK, Abman SH, Elia EG, Avitabile CM, Yung D, Mullen MP, Austin ED, Bates A, Handler SS, Feinstein JA, Ivy DD, Kinsella JP, Mandl KD, Raj JU, Sleeper LA, . Pulmonary Hypertension in Children with Down Syndrome: Results from the Pediatric Pulmonary Hypertension Network Registry. The Journal of pediatrics 2022.

Wang X, Zhang HG, Xiong X, Hong C, Weber GM, Brat GA, Bonzel CL, Luo Y, Duan R, Palmer NP, Hutch MR, Gutiérrez-Sacristán A, Bellazzi R, Chiovato L, Cho K, Dagliati A, Estiri H, García-Barrio N, Griffier R, Hanauer DA, Ho YL, Holmes JH, Keller MS, Klann MEng JG, L'Yi S, Lozano-Zahonero S, Maidlow SE, Makoudjou A, Malovini A, Moal B, Moore JH, Morris M, Mowery DL, Murphy SN, Neuraz A, Yuan Ngiam K, Omenn GS, Patel LP, Pedrera-Jiménez M, Prunotto A, Jebathilagam Samayamuthu M, Sanz Vidorreta FJ, Schriver ER, Schubert P, Serrano-Balazote P, South AM, Tan ALM, Tan BWL, Tibollo V, Tippmann P, Visweswaran S, Xia Z, Yuan W, Zöller D, Kohane IS, Avillach P, Guo Z, Cai T, . SurvMaximin: Robust federated approach to transporting survival risk prediction models. Journal of biomedical informatics 2022.

Torous J, Stern AD, Bourgeois FT. Regulatory considerations to keep pace with innovation in digital health products. NPJ digital medicine 2022.

Levy S, Wisk LE, Minegishi M, Ertman B, Lunstead J, Brogna M, Weitzman ER. Association of Screening and Brief Intervention With Substance Use in Massachusetts Middle and High Schools. JAMA network open 2022.

Nielsen M, Presti M, Sztupinszki Z, Jensen AWP, Draghi A, Chamberlain CA, Schina A, Yde CW, Wojcik J, Szallasi Z, Crowther MD, Svane IM, Donia M. Co-existing alterations of MHC class I antigen presentation and IFNγ signaling mediate acquired resistance of melanoma to post-PD-1 immunotherapy. Cancer immunology research 2022.